170 related articles for article (PubMed ID: 34023135)
1. Pneumococcal immunity and PCV13 vaccine response in SOT-candidates and recipients.
Blanchard-Rohner G; Enriquez N; Lemaître B; Cadau G; Giostra E; Hadaya K; Meyer P; Gasche-Soccal PM; Berney T; van Delden C; Siegrist CA
Vaccine; 2021 Jun; 39(26):3459-3466. PubMed ID: 34023135
[TBL] [Abstract][Full Text] [Related]
2. A randomized, controlled trial comparing the immunogenicity and safety of a 23-valent pneumococcal polysaccharide vaccination to a repeated dose 13-valent pneumococcal conjugate vaccination in adult liver transplant recipients.
Eriksson M; Käyhty H; Lahdenkari M; Mäkisalo H; Anttila VJ
Vaccine; 2021 Apr; 39(17):2351-2359. PubMed ID: 33812743
[TBL] [Abstract][Full Text] [Related]
3. A randomized, controlled trial comparing the immunogenecity and safety of a 23-valent pneumococcal polysaccharide vaccination to a repeated dose 13-valent pneumococcal conjugate vaccination in kidney transplant recipients.
Eriksson M; Käyhty H; Saha H; Lahdenkari M; Koskinen P; Mäkisalo H; Anttila VJ
Transpl Infect Dis; 2020 Aug; 22(4):e13343. PubMed ID: 32473046
[TBL] [Abstract][Full Text] [Related]
4. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
[TBL] [Abstract][Full Text] [Related]
5. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
Nuorti JP; Whitney CG;
MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006-2018.
Andrews N; Kent A; Amin-Chowdhury Z; Sheppard C; Fry N; Ramsay M; Ladhani SN
Vaccine; 2019 Jul; 37(32):4491-4498. PubMed ID: 31272872
[TBL] [Abstract][Full Text] [Related]
7. Direct effectiveness of pneumococcal polysaccharide vaccine against invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia in elderly population in the era of pneumococcal conjugate vaccine: A case-control study.
Kim JH; Chun BC; Song JY; Kim HY; Bae IG; Kim DM; Choi YH; Jun YH; Choi WS; Kang SH; Kwon HH; Jeong HW; Kee SY; Hur J; Chung JW; Yoon YK; Sohn JW; Yang KS; Kim MJ
Vaccine; 2019 May; 37(21):2797-2804. PubMed ID: 31005428
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to 23-valent pneumococcal polysaccharide in immunocompetent adults: A systematic review and meta-analysis.
Vadlamudi NK; Parhar K; Altre Malana KL; Kang A; Marra F
Vaccine; 2019 Feb; 37(8):1021-1029. PubMed ID: 30685252
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of age.
Ermlich SJ; Andrews CP; Folkerth S; Rupp R; Greenberg D; McFetridge RD; Hartzel J; Marchese RD; Stek JE; Abeygunawardana C; Musey LK
Vaccine; 2018 Oct; 36(45):6875-6882. PubMed ID: 29559167
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in 23-valent pneumococcal polysaccharide vaccine-naïve and previously immunized adult patients with severe chronic kidney disease.
Ulanova M; Huska B; Desbiens A; Gaultier GN; Domonkos V; McCready WG
Vaccine; 2021 Jan; 39(4):699-710. PubMed ID: 33358702
[TBL] [Abstract][Full Text] [Related]
11. Application of the screening and indirect cohort methods to evaluate the effectiveness of pneumococcal vaccination program in adults 75 years and older in Taiwan.
Su WJ; Chuang PH; Chang LY; Lo HY; Chiang CS; Wang ET; Yang CH
BMC Infect Dis; 2021 Jan; 21(1):45. PubMed ID: 33423657
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppressive drugs impairs antibody response of the polysaccharide and conjugated pneumococcal vaccines in patients with Crohn's disease.
Kantsø B; Halkjær SI; Thomsen OØ; Belard E; Gottschalck IB; Jørgensen CS; Krogfelt KA; Slotved HC; Ingels H; Petersen AM
Vaccine; 2015 Oct; 33(41):5464-5469. PubMed ID: 26275480
[TBL] [Abstract][Full Text] [Related]
13. The effect of pneumococcal immunization on total and antigen-specific B cells in patients with severe chronic kidney disease.
Gaultier GN; McCready W; Ulanova M
BMC Immunol; 2019 Nov; 20(1):41. PubMed ID: 31718534
[TBL] [Abstract][Full Text] [Related]
14. Impact of the pediatric 13-valent pneumococcal conjugate vaccine on serotype distribution and clinical characteristics of pneumococcal pneumonia in adults: The Japan Pneumococcal Vaccine Effectiveness Study (J-PAVE).
Sando E; Suzuki M; Furumoto A; Asoh N; Yaegashi M; Aoshima M; Ishida M; Hamaguchi S; Otsuka Y; Morimoto K
Vaccine; 2019 May; 37(20):2687-2693. PubMed ID: 30975569
[TBL] [Abstract][Full Text] [Related]
15. Antibody responses after sequential vaccination with PCV13 and PPSV23 in kidney transplant recipients.
Mülling N; van de Sand L; Völk K; Aufderhorst UW; van der Linden M; Horn PA; Kribben A; Wilde B; Krawczyk A; Witzke O; Lindemann M
Infection; 2023 Dec; 51(6):1703-1716. PubMed ID: 37243960
[TBL] [Abstract][Full Text] [Related]
16. Early Streptococcus pneumoniae serotype changes in Utah adults after the introduction of PCV13 in children.
Kendall BA; Dascomb KK; Mehta RR; Stockmann C; Mason EO; Ampofo K; Pavia AT; Byington CL
Vaccine; 2016 Jan; 34(4):474-478. PubMed ID: 26706276
[TBL] [Abstract][Full Text] [Related]
17. Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed): in older adults.
Sanford M
Drugs; 2012 Jun; 72(9):1243-55. PubMed ID: 22686616
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
Peterson JT; Stacey HL; MacNair JE; Li J; Hartzel JS; Sterling TM; Benner P; Tamms GM; Musey LK
Hum Vaccin Immunother; 2019; 15(3):540-548. PubMed ID: 30427749
[TBL] [Abstract][Full Text] [Related]
19. Decreased immune response to pneumococcal conjugate vaccine after 23-valent pneumococcal polysaccharide vaccine in children.
Sigurdardottir ST; Center KJ; Davidsdottir K; Arason VA; Hjalmarsson B; Elisdottir R; Ingolfsdottir G; Northington R; Scott DA; Jonsdottir I
Vaccine; 2014 Jan; 32(3):417-24. PubMed ID: 24300594
[TBL] [Abstract][Full Text] [Related]
20. Pneumococcal Vaccination in Adults: What Can We Learn From Observational Studies That Evaluated PCV13 and PPV23 Effectiveness in the Same Population?
Dunne EM; Cilloniz C; von Mollendorf C; Lewnard J; Grant LR; Slack MPE; Jodar L; Theilacker C; Gessner BD
Arch Bronconeumol; 2023 Mar; 59(3):157-164. PubMed ID: 36681604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]